Close Menu

NEW YORK – Ranjit Manchanda knows evidence alone does not inevitably lead to policy changes. But that hasn't stopped him from generating it.

The Queen Mary University of London researcher — a clinical senior lecturer in experimental cancer medicine and consultant gynecological oncologist at the QMUL Barts Cancer Institute — is convinced that a significant number of breast and ovarian cancer cases could be staved off by screening for a handful of inherited founder mutations in the BRCA1 and BRCA2 genes in individuals of Ashkenazi Jewish ancestry.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.